Dr. Shan Liu is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. Shan focuses on patent prosecution, strategic patent counseling, and IP due diligence in the life sciences industry. She has extensive scientific experience in synthetic organic chemistry, drug discovery, physical chemistry, spectroscopy, carbohydrates, structural biology, and cancer biology.
Prior to joining the firm, Shan worked as a patent agent in a Boston-based law firm, where she represented a number of pharmaceutical and biotechnology companies. She started her legal career as a patent agent at the National Institute of Allergy and Infectious Diseases within the National Institutes of Health (NIH), where she managed IP protection for vaccine inventions, negotiated research agreements, and marketed technologies for collaboration and licensing. While at the NIH, Shan completed the organization's technology transfer certification program.
Shan received her Ph.D. in chemistry from the University of Georgia, where she synthesized small-molecule substrates and screened their interactions with a glycoprotein target for structure-based drug design. Subsequently, Shan joined the National Cancer Institute within NIH and conducted her postdoctoral training in investigating protein-protein interactions involved in carcinogenesis.EDUCATION:
- Ph.D., Chemistry, University of Georgia, 2008
Concentration in Organic Chemistry
- B.S., Chemistry, Beijing University of Chemical Technology, 2003
- Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
- Co-author with D.M. Hoffmeister, V. Norviel, P. Girinath, and C. Andres, "There's a Lot to Like About Hamburg's Legacy at the FDA," Law360, February 9, 2015
- First author with Y. Chen, J. Li, T. Huang, S. Tarasov, A. King, A.M. Weissman, R.A. Byrd, and R. Das, "Promiscuous Interactions of gp78 E3 Ligase CUE Domain with Polyubiquitin Chains Aid Ubiquitination of Substrates," 20(12) Structure 2138-50, 2012
- First author with L. Meng, K. Moremen, and J. Prestegard, "NMR Structural Characterization of the Substrates Bound to Alpha-2, 6-Sialyltransferase ST6Gal1," 48(47) Biochemistry 11211-11219, 2009
- First author with A. Venot, L. Meng, F. Tian, K. Moremen, G. Boons, and J. Prestegard, "Spin-Labeled Analogs of CMP-NeuAc as NMR Probes of the Alpha-2, 6-Sialyltransferase ST6Gal1," 14(4) Chemistry & Biology (CELL) 409-418, 2007
- U.S. Patent and Trademark Office